Biotech | February 23, 2022
Merck completes acquisition of biopharma CDMO Exelead
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The grants are expected to be received over the next three years, commencing March 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Dr. Raman has succeeded Victoria Richon
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Adds five years of market exclusivity on approval
Subscribe To Our Newsletter & Stay Updated
